Theragnostic Biomarkers

Firalis SA, a bioanalytical services and biomarker-based products provider to biopharma, biotechnology companies and academia, and also participant of the RABIOPRED EC Funded Project, develops a next‑generation sequencing (NGS)-based theragnostic tool to identify likely non-responders from responders to anti‑TNFα therapy for rheumatoid arthritis (RA).

RA is a chronic inflammatory disease that affects millions of people in the United States and Western Europe.  TNFα-inhibiting therapies, the blockbusters representing a multibillion dollar market, have been a major breakthrough in the treatment of RA. However, these drugs are found to lack efficacy in an estimated 30 to 40 % of patients (non-responders). The RABIOPRED tool aims to identify the non-responders to improve patient management. Firalis develops, validates and deploys clinically RABIOPRED, a BIOmarker assay to PREDict treatment response in RA, using the NGS-based HTG EdgeSeq system.

“We are pleased to expand our relationship through this personalized medicine initiative,” said TJ Johnson, President and CEO of HTG.

Millions of RA patients are treated with TNFα-inhibiting agents but the clinicians currently are unable to predict patient response to these expensive biologicals,” said Hüseyin Firat, President & CEO of Firalis, and TcLand Expression, the latter being the coordinator of RABIOPRED Project. “We believe the ability to predict response to anti‑TNFα treatment would greatly improve clinical decision-making, improve health outcomes for RA patients, and contribute to cost reduction and sustainability of the health care system.